Revelation Biosciences Inc (REVB) concluded trading on Tuesday at a closing price of $0.46, with 5.28 million shares of worth about $2.43 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -74.25% during that period and on December 31, 2024 the price saw a gain of about 19.73%. Currently the company’s common shares owned by public are about 8.36M shares, out of which, 8.35M shares are available for trading.
Stock saw a price change of 52.45% in past 5 days and over the past one month there was a price change of -39.34%. Year-to-date (YTD), REVB shares are showing a performance of -96.93% which decreased to -96.93% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.28 but also hit the highest price of $25.26 during that period. The average intraday trading volume for Revelation Biosciences Inc shares is 1.16 million. The stock is currently trading 18.87% above its 20-day simple moving average (SMA20), while that difference is down -29.93% for SMA50 and it goes to -67.32% lower than SMA200.
Revelation Biosciences Inc (NASDAQ: REVB) currently have 8.36M outstanding shares and institutions hold larger chunk of about 1.18% of that.
The stock has a current market capitalization of $4.61M and its 3Y-monthly beta is at 0.27. It has posted earnings per share of -$16.75 in the same period. It has Quick Ratio of 1.64 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for REVB, volatility over the week remained 34.84% while standing at 20.75% over the month.
Analysts are in expectations that Revelation Biosciences Inc (REVB) stock would likely to be making an EPS of -0.43 in the current quarter, while forecast for next quarter EPS is -0.54 and it is -2.12 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.43 which is -0.34 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -35.72 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -1311.32% while it is estimated to increase by 71.59% in next year.
